Evaluating Tirzepatide for treating alcohol use disorder and obesity in adults
Official title: Phase II Evaluation of Tirzepatide in Adults with Alcohol Use Disorder and Overweight or Obesity
Funded at University of Southern California · NIH-10999946 · Data updated 2026-11-12
This study is looking at how well Tirzepatide, a new weight loss medication, can help adults who are overweight or obese and also have trouble with alcohol use, by seeing if it can reduce their drinking and help them lose weight for better health.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project start | September 15, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $211,247 |
| NIH project number | 1R21AA031892-01 |
| Project ID | NIH-10999946 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults over 21 years old who have both alcohol use disorder and are classified as overweight or obese.
✕Less likely to help
Patients who do not have alcohol use disorder or who are not overweight or obese may not benefit from this research.
What this research studies
This research investigates the effects of Tirzepatide, a medication recently approved for weight loss, on adults who struggle with alcohol use disorder and are overweight or obese. The study aims to determine if this dual-action drug can help reduce alcohol consumption while also promoting weight loss, thereby improving overall health outcomes. Participants will be monitored for changes in their alcohol intake, body weight, and cardiovascular health over the course of the study. The approach combines clinical assessments with patient-reported outcomes to evaluate the medication's effectiveness.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that addresses both alcohol use disorder and obesity, potentially improving health and quality of life for affected individuals.
How similar studies have gone: Previous research has shown promising results with GLP-1 receptor agonists in reducing alcohol consumption and aiding weight loss, suggesting that this approach may be effective.
Where this research is happening
-
University of Southern California
Los Angeles, United States Active
Researchers
- Principal investigator: Hendershot, Christian S — University of Southern California
- Study coordinator: Hendershot, Christian S
Related research
Other NIH-funded projects on the same topics.
-
Tirzepatide for adults with alcohol use disorder and overweight or obesity
This will see if the weight-loss medication tirzepatide can help adults with alcohol use disorder who are overweight or obese cut back on drinking and improve health measures.
-
Mindful Movement: guided imagery app to boost activity in adults with overweight or obesity
A researcher-led plan to create and test an easy-to-use guided imagery app that helps adults with overweight or obesity stay more physically active.
-
Adding yoga to a weight-loss program for adults with overweight or obesity
This trial compares whether adding regular yoga to a standard behavioral weight-loss program helps adults with overweight or obesity lose more weight over 12 months.
-
Investigating how yoga can enhance weight loss in adults with obesity
This study is looking at whether adding yoga to a weight loss program helps adults who are overweight or obese lose more weight and improve their health compared to just doing regular exercise, and you could help us learn more about this by joining!
-
Functional Connectivity-Guided TMS for Alcohol Use Disorder
A new approach uses targeted brain stimulation to help people with alcohol use disorder stay abstinent longer by focusing treatment on specific brain circuits.
-
Alcohol Use Disorder and Suicidal Behavior: Finding Why They Occur Together
A study using Swedish population data to understand why alcohol use disorder relates to suicidal thoughts and acts, with the goal of improving risk prediction and prevention.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.